louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01354509: Normothermia Protocol for Traumatic Brain Injury Patients
Official title: Normothermia Protocol for Traumatic Brain Injury Patients: An Outcome Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Traumatic Brain Injury
Keywords: Normothermia
fever control
Outcome study
Lead sponsor: Medivance, Inc.
Sponsor class: INDUSTRY
First posted: 2011-05-17
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Severe TBI patients(GCS 3-9) admitted to ICU

Brief summary: Comparison between a normothermia protocol and current protocol (acetaminophen plus blankets)

1. Normothermia Protocol is successful in achieving and maintaining normal temperature in moderate to severe Traumatic Brain Injury (TBI) patients.(using Arctic Sun for 96 hrs from admission to Neuro ICU)
2. Normothermia is translated into improved neurologic Outcome and survival compared to standard of care (Physician management)


Eligibility criteria: Inclusion Criteria:

* Severe TBI patients(GCS 3-9) admitted to ICU

Exclusion Criteria:

* Less than 18 years OLD.
* Bleeding disorders.
* Pregnancy/Breastfeeding.
* Hepatic Encephalopathy.
* Spinal cord injury (know or new)
* Fever \>100 F prior to randomization.
* Blood Alcohol level \>80
* Participation in other Research trial.
* Inability/unwilling to obtain Informed consent.
* Terminal illness(not expected to survive 3-6 months)
* Not expected to survive 24 hrs.

Primary outcomes:
measure: Effectiveness of the Normothermia protocol
timeFrame: 5 days
measure: Temperature vs ICP
timeFrame: 5 days
measure: Neurologic Outcome of the 2 patient populations
timeFrame: 1month, 3 months, 6 months
Secondary outcomes:
measure: Mortality
timeFrame: 5 days, 3 months, 6 months
Other outcomes:
Locations:
city: St Louis
country: United States
facility: Mercy St John's Medical Center
state: Missouri
Study officials:
affiliation: Mercy St John's Medical Center
name: Farid Sadaka, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05206409: Prediction of Delivery Mode by Ultrasound-assessed Fetal Position in Nulliparous Women With Prolonged First Stage of Labor.
Official title: Prediction of Delivery Mode by Ultrasound-assessed Fetal Position in Nulliparous Women With Prolonged First Stage of Labor.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prolonged Labor
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-01-25
Enrollment: 382
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Nulliparous women with delayed first stage of Labor

Brief summary: In the past years, numerous studies have been published on the use of ultrasound during labor, showing this is an effective, accurate and objective tool for the assessment of the fetal head position and station. Literature affirmed that traditional transvaginal digital examination is highly subjective and dependent on the operator's experience. On the contrary, the use of intrapartum suprapubic transabdominal ultrasound can improve accuracy in determination of fetal head position and the precise knowledge of the location of specific fetal head landmarks in relationship to maternal pelvis. Intrapartum ultrasound will assist obstetricians in the diagnosis of normal labor progression, suggesting when medical and or operative intervention should be taken in case of complications.


Eligibility criteria: Inclusion Criteria:

* nulliparous women
* Singleton pregnancy
* prolonged first stage of Labor
* average fetal weight
* gestational age at or beyond 37 weeks

Exclusion Criteria:

* IUFD
* malpresentation

Primary outcomes:
measure: Mode of delivery
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: AinShams Maternity Hospital
Study officials:
References:
Clinical trial NCT02345109: Clinical Trial of Transtek Body Fat Analyzer (GBF-835-N2 & Other 7 Models)
Official title: Verify the Functions and Efficiency of Transtek (Trade Mark) Body Fat Analyzer, 8 Models
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Weight
Body Fat Disorder
Keywords: weight
total body water
body fat
muscle mass
bone mass
BMI
visceral fat
calories
Lead sponsor: BTS International
Sponsor class: OTHER
Collaborators: name: West China Hospital
First posted: 2015-01-26
Enrollment: 60
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL

Brief summary: The clinical protocol of the clinical testing of this device:

1. Objective of the test: To verify the functions and efficiency of devices.
2. Test methods and procedures: Comparison Test.
3. Device Under Test (DUT): Transtek Body Fat Analyzer, Model: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, LS202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
4. Comparison device: TRANSTEK GBF-1251-B and Tanita BC-533.
5. Study endpoints: DUT and the comparison device are substantial equivalence.
6. Statistical methodology used: Description of statistical methods.

Detailed description: 1. Test Purpose:

   The aim of clinical test is to collect BMI, body fat, total body water, muscle mass, bone mass, calorie, and visceral fat reading value which measured by DUT and reference device.
2. Target Subject:

   The subject database shall contain at least 30 male and 30 female subjects and all above 10 years old.
3. Test procedures:

   1. Record the name, age, gender, and height of each subject.
   2. Let subject seated calmly for two minutes before test, dry the feet.
   3. Use device to measure weight, body fat, total body water, bone mass, and muscle mass; record reading value.
   4. For each subject, repeat 3) to get 3 pairs measurements.
   5. Repeat step 1) to 4) for every device (DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, LS202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus; and reference device: GBF-1251-B and BC-533).
   6. Repeat step 1) to 5) for each subject.
4. Note:

   1. No motion and speaking are allowed during the measurement.
   2. All DUT use the same algorithms and contact the patient at the same body locations (feet), and operate on the same frequency.
   3. Test environment: Temperature: 22±1℃; Relative humidity: 40\~70%.

Eligibility criteria: Inclusion Criteria:

* Male, female

Exclusion Criteria:

* Below 10 years old

Primary outcomes:
measure: BMI (Body Mass Index)
timeFrame: 5 Days
Secondary outcomes:
measure: Weight
timeFrame: 1 Day
Other outcomes:
Locations:
city: Chengdu
country: China
facility: Wuhou District Hospital
state: Sichuan
Study officials:
affiliation: Wuhou District Hospital
name: Guoqing Li, Director
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05102409: An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
Official title: An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects With Dry Eye Disease in a Dry Eye Chamber
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dry Eye
Lead sponsor: Aldeyra Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-11-01
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber


Eligibility criteria: Inclusion Criteria:

1. Eighteen (18) to70 years of age at the time of screening (either gender and any race).
2. Ability to provide written informed consent.
3. Reported history of dry eye for at least 6 months prior to Visit 1.

Exclusion Criteria:

1. Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal) or active ocular inflammation at Visit 1.
2. Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial.
3. A condition that the investigator feels may put the subject at significant risk may confound the study results or may interfere significantly with the subject's participation in the trial.
4. Inability or unwillingness to follow instructions, including participation in all study assessments/procedures and visits.

Primary outcomes:
measure: Change From Baseline in Ocular Discomfort
timeFrame: The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.
measure: Change From Baseline in Ocular Itching
timeFrame: The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.
Secondary outcomes:
Other outcomes:
Locations:
city: Mississauga
country: Canada
facility: Cliantha Research
state: Ontario
Study officials:
References:
Clinical trial NCT00730509: Effects of 5-Methyltetrahydrofolate and Vitamin B12 Supplemetation on Red Cell Membrane in Children With Cystic Fibrosis
Official title: Preliminary Evidences of Active Form of Folic Acid and Vitamin B12 Supplementation to Ameliorate Cell Membrane in Children With Cystic Fibrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cystic Fibrosis
Keywords: cystic fibrosis
folate
vitamin B12
Lead sponsor: Universita di Verona
Sponsor class: OTHER
First posted: 2008-08-08
Enrollment: 31
Sex: ALL
Minimum age (years): 3
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to determine whether 5 - methyltetrahydrofolate and vitamin B12 supplementation can ameliorate cell plasma membrane features in pediatric patients with cystic fibrosis

Detailed description: Cystic fibrosis (CF) is one of the most common fatal autosomal recessive disorders in the Caucasian population caused by mutations of gene for the cystic fibrosis transmembrane conductance regulator (CFTR). New experimental therapeutic strategies for CF propose a diet supplementation to affect the plasma membrane fluidity and to modulate the cellular amplified inflammatory response in CF target organs. Red blood cells (RBCs) were used to investigate plasma membrane, because RBCs share lipid, protein composition and organization with other cell types.

Eligibility criteria: Inclusion Criteria:

* cystic fibrosis

Exclusion Criteria:

* diabetes
* chronic infections of the airways
* regular antibiotics intake

Primary outcomes:
measure: We evaluated membrane protein oxidative damage of red cells
timeFrame: 6 months
Secondary outcomes:
measure: we evaluated cation transport pathways of red cells
timeFrame: 6 months
Other outcomes:
Locations:
city: Verona
country: Italy
facility: Verona University
Study officials:
affiliation: Verona University
name: Lisa M. Bambara, MD
role: STUDY_DIRECTOR
References:
citation: Scambi C, Guarini P, De Franceschi L, Bambara LM. Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients? J Cyst Fibros. 2006 Aug;5(3):197-9. doi: 10.1016/j.jcf.2006.01.006. Epub 2006 Mar 3.
citation: Scambi C, De Franceschi L, Guarini P, Poli F, Siciliano A, Pattini P, Biondani A, La Verde V, Bortolami O, Turrini F, Carta F, D'Orazio C, Assael BM, Faccini G, Bambara LM. Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial. PLoS One. 2009;4(3):e4782. doi: 10.1371/journal.pone.0004782. Epub 2009 Mar 11.
Clinical trial NCT00229307: Prolonged Exposure (PE) Treatment for Post Traumatic Stress Disorder (PTSD) 20 Minutes Versus 40 Minutes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: PTSD
Keywords: Post traumatic stress disorder
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2005-09-29
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparing the efficacy of 40 minutes PE treatment to 20 minutes of the same treatment


Eligibility criteria: Inclusion Criteria:

* PTSD

Exclusion Criteria:

* Psychotic symptoms
* Dissociation
* Drug or Alcohol dependence

Primary outcomes:
measure: PSS-i
timeFrame: 15 weeks and 1-year follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat-Gan
country: Israel
facility: Chaim Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Nitza Nacasch, MD
role: STUDY_CHAIR
affiliation: Sheba Medical Center
name: Joseph Zohar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06153407: Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve
Official title: Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bicuspid Aortic Valve
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2023-12-01
Enrollment: 240
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient who have bicuspid aortic valve

Brief summary: This study is to elucidate the impact of germline mutations and clonal hematopoiesis (CHIP) on the progression of early aortic valve calcification in patients with bicuspid aortic valves. The study will be conducted over a recruitment period of one year and a follow-up observation period of two years. Considering a 2-year event rate and a 33% occurrence rate of clonal hematopoiesis, each group requires a minimum of 102 participants. Accounting for a 15% dropout rate, a total of 120 participants are needed for each group (type I error (α) = 5%, type II error (β) = 20%). Therefore, the total study population, including patients with normal aortic valve function, is set at 240 participants.


Eligibility criteria: Inclusion Criteria:

1. Patients with confirmed bicuspid aortic valves based on cardiac imaging (echocardiography, CT, MRI) or surgical findings.
2. Early aortic valve calcification group: Patients aged 20-80 with moderate or greater aortic valve stenosis/regurgitation.
3. Normal functioning aortic valve group: Patients aged 20-80 with mild or less aortic valve stenosis/regurgitation.
4. Patients who understand the purpose of the study and voluntarily consent to participate.

Exclusion Criteria:

1. Patients with malignant neoplastic diseases or other conditions, such as cerebrovascular accidents, which predict survival of less than 6 months.
2. Patients with unclear presence of bicuspid aortic valves.
3. Patients with stage 3 or higher chronic kidney disease.
4. Patients with other inherited cardiac conditions.
5. Patients with cognitive impairment or hemodynamically unstable patients who have difficulty understanding the study content.

Primary outcomes:
measure: Presence of germline mutation
timeFrame: 2 years follow-up
measure: Clonal hematopoiesis of indeterminate potential (CHIP) mutation
timeFrame: 2 years follow-up
Secondary outcomes:
measure: Progression of aortic valve calcification
timeFrame: 2 years follow-up
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine
Study officials:
affiliation: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine
name: Iksung Cho
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02707107: MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Adult Human Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Serious Gram-negative Infections
Lead sponsor: Wockhardt
Sponsor class: INDUSTRY
Collaborators: name: Quintiles, Inc.
First posted: 2016-03-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Study to evaluate the safety, tolerability and pharmacokinetics of multiple escalating doses of intravenous WCK 5222 (Zidebactam and Cefepime) in healthy adult human subjects.


Eligibility criteria: Inclusion Criteria:

1. Have a body mass index of 18 to 30 kg/m2 (both inclusive) calculated as weight (kg)/height(m2).
2. Resting supine blood pressure of 90 to 139 (systolic)/40 to 89 (diastolic) mmHg and a resting pulse rate of 40 to 100 beats per minute.
3. Calculated creatinine clearance ≥80 mL/min (Cockcroft-Gault method).
4. All values of hematology, serum chemistry, coagulation, and urinalysis showing no clinically significant deviations from normal as judged by the Principal Investigator.

Exclusion Criteria:

1. Participation in another investigational drug or device study or treated with an investigational product within 30 days or 5 half-lives, whichever is longer, before investigational product administration in this study.
2. History/evidence of clinically relevant pathology related to the cardiovascular system, central nervous system, respiratory tract, gastrointestinal tract, endocrinology, immunology, hematology or any other systemic disorder/major surgeries, that in the opinion of the Principal Investigator would confound the subject's participation and follow-up in the study.
3. History of clinically significant food or drug allergy, including known hypersensitivity to cefepime or any other related drugs.
4. History of Clostridium difficile induced diarrhea or infection within 1 year before screening.
5. Prior exposure to zidebactam.

Primary outcomes:
measure: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
timeFrame: 14 days
Secondary outcomes:
measure: Maximum plasma concentration
timeFrame: 7 days
measure: Time to Cmax
timeFrame: 7 days
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Quintiles
state: Kansas
Study officials:
References:
Clinical trial NCT01672307: Minoxidil 2% for Eyebrow Enhancement
Official title: Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypotrichosis of Eyebrows
Thinning Eyebrows
Keywords: hypotrichosis of eyebrows
thinning eyebrows
minoxidil
placebo
randomized
Lead sponsor: Mae Fah Luang University Hospital
Sponsor class: OTHER
First posted: 2012-08-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare minoxidil 2% versus placebo in enhancement of eyebrows.


Eligibility criteria: Inclusion Criteria:

* male or female aged 18-40 years
* hypotrichosis of eyebrows
* healthy
* informed consent obtained

Exclusion Criteria:

* no underlying diseases
* no alopecia areata or trichotillomania
* no thyroid diseases
* no pregnancy or breast feeding
* no previous eyebrow tattoo, trauma or accident.
* no history of eyebrow or hair medications in 6 months
* no history of minoxidil or its ingredient allergy
* no history of eyebrow surgery.

Primary outcomes:
measure: The change of global photographic assessment after 16 weeks from baseline
timeFrame: baseline and 16 weeks
Secondary outcomes:
measure: The change of hair diameter after 16 weeks from baseline
timeFrame: baseline and 16 weeks
Other outcomes:
measure: The change in number of hairs after 16 weeks from baseline
timeFrame: baseline and 16 weeks
measure: Number of participants with adverse events. Adverse events include any skin rashes or symptoms.
timeFrame: 16 weeks
measure: Patient satisfaction by self-assessment questionnaires
timeFrame: 16 weeks
Locations:
city: Bangkok
country: Thailand
facility: MFL University Hospital (Bangkok)
Study officials:
affiliation: MFL University Hospital (Bangkok)
name: Chuchai Tanglertsampan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01330407: Comparative Assessment of Adjuvant Effect of Cultured Epidermal Autografts Versus Skin Allografts on Wound Healing of Burns Treated With Widely Expanded Skin Autograft Using Meek Micrografting Technique MEEKADEAU
Official title: Comparative Assessment of Adjuvant Effect of Cultured Epidermal Autografts Versus Skin Allografts on Wound Healing of Burns Treated With Widely Expanded Skin Autograft Using Meek Micrografting Technique MEEKADEAU
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Burn Wounds
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2011-04-07
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators intend to conduct a comparative, monocentric prospective double-blind study with intra-subject randomization, to compare the results on wound healing of 2 adjuvant treatments to Meek micrografting technique : Cultured Epidermal Autografts and cryopreserved skin allografts.

Detailed description: 10 patients presenting burn wounds over 50% of total body surface area, including at least 40 % of deep burns, will be enrolled.

Eligibility criteria: Inclusion Criteria:

1. Males and females between 18 to 60 years of age
2. Burns \> 50% Total Body Surface Area (TBSA), including deep burns \> 40% TBSA (deep partial thickness and full thickness burns).
3. Patients presenting two 300 cm² (30x10cm) non adjacent burn wound areas, of similar depth assessed by Laser Doppler Imaging, on body anterior side, functional areas excepted.
4. Written informed consent, signed by patient or legal representative (if patient unable to sign).
5. Negative pregnancy test

Exclusion Criteria:

1. Chemical or electric burns
2. Short delay life threatening disease, by itself or when associated with burns.
3. Chronic systemic steroïd intake,
4. Pre-existing diseases interfering with wound healing : inherited connective tissue disorder (Ehlers Danlos syndrome, Marfan syndrome), Epidermolysis Bullosa. Medical treatment interfering with wound healing (retinoids..).
5. Prisonners
6. Pregnant women
7. Patient under guardianship.
8. Participation in another investigational trial within this trial

Primary outcomes:
measure: TIME OF HEALING
timeFrame: 2 YEARS
Secondary outcomes:
measure: QUALITY OF HEALING
timeFrame: 2 YEARS
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique Hopitaux de Marseille
Study officials:
affiliation: Assistance Publique hôpitaux de Marseille
name: BERNARD BELAIGUES
role: STUDY_DIRECTOR
References: